Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 50,000 Shares of Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Rating) insider Samuel C. Blackman sold 50,000 shares of the business’s stock in a transaction on Wednesday, June 15th. The shares were sold at an average price of $16.26, for a total transaction of $813,000.00. Following the sale, the insider now owns 1,316,718 shares of the company’s stock, valued at approximately $21,409,834.68. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Shares of DAWN stock opened at $15.79 on Friday. The firm has a fifty day simple moving average of $9.09 and a two-hundred day simple moving average of $12.31. Day One Biopharmaceuticals, Inc. has a 12 month low of $5.44 and a 12 month high of $28.70.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.09). Analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.05 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of DAWN. Citigroup Inc. bought a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter worth $30,000. Royal Bank of Canada bought a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter worth $33,000. Morgan Stanley bought a new stake in shares of Day One Biopharmaceuticals in the 2nd quarter worth $54,000. Metropolitan Life Insurance Co NY bought a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter worth $86,000. Finally, California State Teachers Retirement System grew its stake in shares of Day One Biopharmaceuticals by 58.6% in the 1st quarter. California State Teachers Retirement System now owns 9,687 shares of the company’s stock worth $96,000 after acquiring an additional 3,581 shares in the last quarter. Hedge funds and other institutional investors own 79.02% of the company’s stock.

Separately, Wedbush boosted their price target on shares of Day One Biopharmaceuticals from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, June 13th.

About Day One Biopharmaceuticals (Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Read More

Insider Buying and Selling by Quarter for Day One Biopharmaceuticals (NASDAQ:DAWN)

Want More Great Investing Ideas?

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.